This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment
Child has had a prior nasal surveillance culture grow S. aurues
Child is <18 years of age
Child completed treatment with intranasal mupirocin for S. aureus nasal colonization as part of routine clinical care two or more days before the planned transplant
Child has anticipated hospital length of stay >3 days after completing intranasal mupirocin treatment
Child is a ward of the State
Child with a diagnosis of immunodeficiency or antenatal suspicion for immunodeficiency (e.g., sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency)
Child cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing)
Donor is able to provide informed consent
Parallel
Nasal Microbiota Transplant (NMT)
Biological/Vaccinenasal microbiota transplant
Placebo
Biological/VaccinePlacebo sterile swab
Pediatric nasal microbiome diversity after parent-to-child NMT.
This outcome will be determined by analysis of periodic surveillance swabs collected after intervention.
Click on the lead sponsor to view all of their trials.
